| Sector |
Agriculture
|
Compare with Sector peers |
| Industry |
Agriculture
|
Compare with Industry peers |
| Website | http://www.nathbiogenes.com | |
| Market Cap | 383.31 Cr. | |
| Enterprise Value(EV) | 496.12 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 21.31 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 9.47 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | - | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 319.86 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 0.63 | Calculated using Price: 201.70 |
| Dividend Yield | 0.99 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.90 Cr. | 19,004,000 Shares |
| FaceValue | 10 | |
| About Nath Bio-Genes (India) Ltd. | ||
| The company is an indigenous seed company is poised to play a more significant role in agricultural development, farmer prosperity and promotion of indigenously developed agricultural technologies. | ||
| 1 Day |
|
-1.32% |
| 1 Week |
|
+1.08% |
| 1 Month |
|
+6.69% |
| 3 Month |
|
-7.24% |
| 6 Month |
|
+8.18% |
| 1 Year |
|
+23.33% |
| 2 Year |
|
-11.36% |
| 5 Year |
|
-57.03% |
| 10 Year |
|
+147.33% |
| 4 years | 2012-03 | 2013-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 20.12 | 22.76 | -22.48 | 6.28 | |
| Return on Capital Employed (%) | 19.09 | 23.88 | -14.84 | 7.06 | |
| Return on Assets (%) | 7.73 | 8.5 | -15.03 | 4.57 |
| Particulars | 5 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 46 | 57 | 542 | 573 | 604 | |
| Non Curr. Liab. | 1 | 2 | 3 | 3 | 3 | |
| Curr. Liab. | 72 | 98 | 194 | 216 | 239 | |
| Minority Int. | 0 | 0 | ||||
| Equity & Liab. | 119 | 157 | 739 | 793 | 847 | |
| Non Curr. Assets | 23 | 38 | 272 | 272 | 271 | |
| Curr. Assets | 96 | 120 | 468 | 521 | 576 | |
| Misc. Exp. not W/O | ||||||
| Total Assets | 119 | 157 | 739 | 793 | 847 |
| Particulars | 5 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 124 | 138 | 278 | 301 | 335 | |
| Other Income | 1 | 1 | 2 | 1 | 0 | |
| Total Income | 125 | 138 | 280 | 302 | 335 | |
| Total Expenditure | -109 | -118 | -241 | -253 | -283 | |
| PBIDT | 16 | 20 | 39 | 49 | 52 | |
| Interest | -2 | -4 | -11 | -10 | -10 | |
| Depreciation | -5 | -5 | -3 | -3 | -3 | |
| Taxation | 0 | -1 | -4 | -1 | -2 | |
| Exceptional Items | -89 | 3 | ||||
| PAT | 9 | 12 | -67 | 35 | 40 | |
| Minority Interest | 0 | 0 | ||||
| Share Associate | ||||||
| Other Related Items | ||||||
| Consolidated Net Profit | 9 | 12 | -67 | 35 | 40 | |
| Adjusted EPS | 6 | 7 | -35 | 18 | 21 |
| Particulars | 4 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 14 | 17 | 38 | ||
| Cash Fr. Inv. | -21 | -20 | -3 | ||
| Cash Fr. Finan. | 6 | -22 | -2 | ||
| Net Change | -1 | -25 | 34 | ||
| Cash & Cash Eqvt | 2 | 4 | 38 |
|
Tue, 30 Apr 2024
Board Meeting Intimation for 1. Approval Of Audited Financial Results For The Year Ended 31St March 2024. Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2024 inter alia to consider and approve Audited Financial Results for the year ended 31st March 2024. |
|
Wed, 24 Apr 2024
Compliance Certificate Compliance Certificate under Regulation 40 (10) of SEBI (LODR) Regulations 2015 for the period ended 31st March 2024 |
|
Mon, 15 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations 2018 for the period ended 31st March 2024 |
| Fri, 03 May 2024 |
High Delivery Percentage
|
Making Lower Lows for 3 days
|
Making Lower Lows for 2 Days
|
Close Crossing 100 SMA From Above
|
Closing Near 100 SMA
|
